| First Author | Rady I | Year | 2017 |
| Journal | Cancer Lett | Volume | 402 |
| Pages | 16-31 | PubMed ID | 28536009 |
| Mgi Jnum | J:243201 | Mgi Id | MGI:5907915 |
| Doi | 10.1016/j.canlet.2017.05.010 | Citation | Rady I, et al. (2017) Melittin, a major peptide component of bee venom, and its conjugates in cancer therapy. Cancer Lett 402:16-31 |
| abstractText | Melittin (MEL), a major peptide component of bee venom, is an attractive candidate for cancer therapy. This agent has shown a variety of anti-cancer effects in preclinical cell culture and animal model systems. Despite a convincing efficacy data against variety of cancers, its applicability to humans has met with challenges due to several issues including its non-specific cytotoxicity, degradation and hemolytic activity. Several optimization approaches including utilization of nanoparticle based delivery of MEL have been utilized to circumvent the issues. Here, we summarize the current understanding of the anticancer effects of bee venom and MEL on different kinds of cancers. Further, we also present the available information for the possible mechanism of action of bee venom and/or MEL. |
